Statement of Changes in Beneficial Ownership (4)
December 23 2020 - 4:24PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Myers Jason W. |
2. Issuer Name and Ticker or Trading Symbol
Invitae Corp
[
NVTA
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) __X__ Other (specify below) President, Oncology |
(Last)
(First)
(Middle)
C/O INVITAE CORPORATION, 1400 16TH STREET |
3. Date of Earliest Transaction
(MM/DD/YYYY)
12/21/2020 |
(Street)
SAN FRANCISCO, CA 94103
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 12/21/2020 | | S | | 3232 (1) | D | $47.0971 (2)(3) | 806482 | D | |
Common Stock | 12/21/2020 | | S | | 3935 (1) | D | $47.8123 (3)(4) | 802547 | D | |
Common Stock | 12/21/2020 | | S | | 19297 (1) | D | $49.2428 (3)(5) | 783250 | D | |
Common Stock | 12/21/2020 | | S | | 73310 (1) | D | $49.9499 (3)(6) | 709940 | D | |
Common Stock | 12/21/2020 | | S | | 200 (1) | D | $50.545 (3)(7) | 709740 | D | |
Common Stock | 12/22/2020 | | S | | 4700 (1) | D | $51.7264 (3)(8) | 705040 | D | |
Common Stock | 12/22/2020 | | S | | 70942 (1) | D | $52.8417 (3)(9) | 634098 | D | |
Common Stock | 12/22/2020 | | S | | 42338 (1) | D | $53.4344 (3)(10) | 591760 | D | |
Common Stock | 12/22/2020 | | S | | 7011 (1) | D | $54.2706 (3)(11) | 584749 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | The sales of common stock were effected pursuant to a Rule 10b-5 sales plan adopted by the reporting person on October 1, 2020. |
(2) | Represents a weighted average sale price. Actual sale prices ranged from $46.50 to $47.49 per share. |
(3) | Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. |
(4) | Represents a weighted average sale price. Actual sale prices ranged from $47.52 to $48.44 per share. |
(5) | Represents a weighted average sale price. Actual sale prices ranged from $48.54 to $49.53 per share. |
(6) | Represents a weighted average sale price. Actual sale prices ranged from $49.54 to $50.53 per share. |
(7) | Represents a weighted average sale price. Actual sale prices ranged from $50.54 to $50.55 per share. |
(8) | Represents a weighted average sale price. Actual sale prices ranged from $51.08 to $52.07 per share. |
(9) | Represents a weighted average sale price. Actual sale prices ranged from $52.08 to $53.07 per share. |
(10) | Represents a weighted average sale price. Actual sale prices ranged from $53.08 to $54.07 per share. |
(11) | Represents a weighted average sale price. Actual sale prices ranged from $54.08 to $54.57 per share. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Myers Jason W. C/O INVITAE CORPORATION 1400 16TH STREET SAN FRANCISCO, CA 94103 | X |
|
| President, Oncology |
Signatures
|
/s/ Thomas Brida, Attorney-in-Fact | | 12/23/2020 |
**Signature of Reporting Person | Date |
Invitae (NYSE:NVTA)
Historical Stock Chart
From Apr 2024 to May 2024
Invitae (NYSE:NVTA)
Historical Stock Chart
From May 2023 to May 2024